CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-11 | Warden Charles M Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2025-06-11 | Graves Adrienne L Director | Grant or award | +14,000 | 50,000 | ||
| 2025-06-11 | Graves Adrienne L Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2025-06-02 | Waheed Nadia Chief Medical Officer | Sale 10b5-1 | −13,861 | $8.05 | $112K | 206,805 |
| 2025-05-23 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,862 | $7.17 | $13K | 281,623 |
| 2025-05-23 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −2,974 | $7.17 | $21K | 207,104 |
| 2025-05-23 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,024 | $7.18 | $22K | 262,974 |
| 2025-05-23 | Dugel Pravin See Remarks | Sale 10b5-1 | −21,219 | $7.18 | $152K | 3,499,099 |
| 2025-05-08 | LINDSTROM RICHARD L MD Director | Purchase | +10,000 | $6.96 | $70K | 172,704 |
| 2025-04-28 | Dugel Pravin See Remarks | Gift | −200,332 | 3,298,767 | ||
| 2025-02-24 | Dugel Pravin See Remarks | Sale 10b5-1 | −21,475 | $6.87 | $148K | 3,520,318 |
| 2025-02-24 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,061 | $6.87 | $21K | 265,998 |
| 2025-02-24 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −3,009 | $6.87 | $21K | 210,078 |
| 2025-02-24 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,895 | $6.84 | $13K | 283,485 |
| 2025-02-11 | Dugel Pravin See Remarks | Grant or award | +1,250,000 | 2,041,793 | ||
| 2025-02-11 | Dugel Pravin See Remarks | Grant or award | +1,500,000 | 3,541,793 | ||
| 2025-02-11 | Waheed Nadia Chief Medical Officer | Grant or award | +79,000 | 220,666 | ||
| 2025-02-11 | Waheed Nadia Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +237,000 | 237,000 | ||
| 2025-02-11 | Notman Donald See Remarks | Grant or award | +115,000 | 308,444 | ||
| 2025-02-11 | Notman Donald See Remarks | Grant or award · Stock Option (Right to Buy) | +344,115 | 344,115 |
Page 6 of 8 · 158 trades